Pharmaceutical equipment leader by the agency to raise funds, net purchase of more than 70 million yuan

According to data, 195 stocks in the Longhu list from April 22 to June 21 showed the net buying status of institutions, and 24 were net purchases of 100 million by institutionsin addition, during the period, there are five stocks that grew substantially in the first half of 2020 (growth of 50% and above) were robbed by institutions, with Dongfulong's first-half net profit up 50%, and the institution's net purchase of 780.605 million yuan, the top net purchaserecently, the East Fulong market has been more active, so it has also attracted the attention of investors and institutionson June 23,, at 9:30 a.m., Dongfulong was in a different position, adding a sharp increase of -0.37%, a record high (previousregal price)as of 9:32 p.mon the same day, the stock 16.1 yuan / share, turnover of 361.34 million lots, turnover rate of 0.86%, amplitude 2.91%, volume ratio of 18.37June 22, the net inflow amount of the stock was 234 million yuan, the main net inflow was 210 million yuan, the net inflow of the single inflow was 13.3882 million yuan, and the net inflow of retail investors was 103.454 million yuanin the past month, Dongfulong has been on the list of dragons and tigers onceaccording to, Dongfulong was founded in 1993 and landed on the Shenzhen Stock Exchange GEM on February 1, 2011is a global pharmaceutical company to provide pharmaceutical technology, core equipment, system engineering overall solutions of integrated pharmaceutical equipment service providers, mainly engaged in medical freeze-dried machineand and freeze-drying system research and development, design, production, sales and serviceat present, the company has more than 8000 sets of pharmaceutical equipment, pharmaceutical manufacturing systems to serve more than 40 countries and regions around the world more than a thousand well-known pharmaceutical enterprises, widely used in biological products, vaccines, blood products, antibiotics, chemicals, diagnostics, health care products, veterinary drugs, Chinese medicine western and other fields's financial performance, especially profitability, was outstandingaccording to theannual report, in 2019, Dongfulong achieved operating income of RMB2,264 million, up 18.11% YoY, and net profit of RMB146 million, up 106.95% YoY, in the first quarter of 2020, Dongfulong achieved revenue of 503.39 million yuan, and net profit attributable to shareholders of the parent company was RMB4714.8548 million, an increase of 195.982 percent year-on-year and basic earnings per share of RMB0.075talking about the reasons why the first quarter of this year's results continue to be red, DongFulong mentioned that in the first quarter, the company in the pharmaceutical equipment sector to actively protect and promote the delivery plan of domestic and foreign business, continue to implement precision management, improve information management capabilities, strengthen cost control;industry believes that Dongfulong as the domestic pharmaceutical equipment industry leader, benefit from the arrival of the industry inflection point, the future company's revenue is expected to maintain steady growth, profitability gradually improvedin addition, the company's sterile injection equipment and overall solutions benefit from the injection consistency evaluation continued to advance, in recent years, the introduction of new biology, API and disinfection products have broad prospects, the release of that, optimistic about the company's long-term development potentialrecently, in 2020 shanghai area listed companies collective reception day, Dongfulong said that the company as a pharmaceutical overall solution integrated pharmaceutical equipment service provider, will focus on the pharmaceutical industry concerns about the challenges and pressures, explore the "innovative drug manufacturing model", and strive to achieve the vision of smart pharmaceutical company delivery, committed to growing into the world's leading supplier of integrated pharmaceutical equipmentincreased investment and strategic layout in the fields of medical technology and technology and food engineering, expanded the company's industrial chain, and helped the company's medium- and long-term operating performance can continue to growat the same time, the company's management in their own business development, technological innovation and management capacity to improve, but also attach great importance to the company's market value management, since the listing, has been with investors to maintain positive communication and exchanges, stable business performance, regular dividendreturns to shareholders